Michael R. Hale
Affiliations: | Boston College, Newton, MA, United States |
Area:
Med ChemGoogle:
"Michael Hale"Mean distance: 7.6 | S | N | B | C | P |
Parents
Sign in to add mentor| Amir H. Hoveyda | grad student | 1994 | Boston College |
| Harry H. Wasserman | post-doc | 1995 | Yale |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Germann UA, Furey BF, Markland W, et al. (2017) Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (ulixertinib). Molecular Cancer Therapeutics |
| Murphy-Benenato KE, Gingipalli L, Boriack-Sjodin PA, et al. (2015) Negishi cross-coupling enabled synthesis of novel NAD(+)-dependent DNA ligase inhibitors and SAR development. Bioorganic & Medicinal Chemistry Letters |
| Germann U, Furey B, Roix J, et al. (2015) Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance Cancer Research. 75: 4693-4693 |
| Hale MR, Brassington C, Carcanague D, et al. (2015) From fragments to leads: Novel bacterial NAD+-dependent DNA ligase inhibitors Tetrahedron Letters. 56: 3108-3112 |
| Murphy-Benenato KE, Olivier N, Choy A, et al. (2014) Synthesis, Structure, and SAR of Tetrahydropyran-Based LpxC Inhibitors. Acs Medicinal Chemistry Letters. 5: 1213-8 |
| Gao N, McLeod SM, Hajec L, et al. (2014) Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain. Protein Expression and Purification. 104: 57-64 |
| Aronov AM, Tang Q, Martinez-Botella G, et al. (2009) Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. Journal of Medicinal Chemistry. 52: 6362-8 |
| Aronov AM, Baker C, Bemis GW, et al. (2007) Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. Journal of Medicinal Chemistry. 50: 1280-7 |
| Miller JF, Andrews CW, Brieger M, et al. (2006) Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. Bioorganic & Medicinal Chemistry Letters. 16: 1788-94 |
| Conde-Frieboes K, Reynolds LJ, Lio YC, et al. (1996) Activated ketones as inhibitors of intracellular Ca2+-dependent and Ca2+-independent phospholipase A2 Journal of the American Chemical Society. 118: 5519-5525 |